invasive cancer

临床试验

计划入组 14 人 · 首次发布于 2020 年 10 月 5 日

招募中

NCT03019471

Non Invasive Cancer Test (NICT): a Proof of Principle Study.

计划入组 40 人 · 首次发布于 2017 年 1 月 12 日

招募中

NCT07636148

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

计划入组 2,000 人 · 首次发布于 2026 年 6 月 9 日

药物

查看全部 2230 →

Biotech

Approved

BCG vaccine

相关疾病：Non-Invasive Bladder Urothelial Carcinoma, Recurrent Superficial Bladder Cancer，另有 3 项

Small Molecule

Approved

Tamoxifen(Soltamox)

生产企业：Rosemont group ltd, Astrazeneca pharmaceuticals lp，另有 9 家

相关疾病：Breast Cancer, Contralateral Breast Cancer，另有 7 项

C₂₆H₂₉NO · Rx

Small Molecule

Approved

Raloxifene(Evista, Optruma, Raloxifene Teva)

生产企业：Eli lilly and co

相关疾病：Invasive Breast Cancer, Osteoporosis，另有 1 项

C₂₈H₂₇NO₄S · Rx

机构

查看全部 1118 →

bioAffinity Technologies

United States

CENTER WEST CANCER

United States

Orsi Academy

Belgium

资讯

查看全部 15985 →

5个月前

LORD Trial Shows Active Surveillance May Be Safe Alternative to Surgery for Low-Risk DCIS

去年

NIAGARA Trial: Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer

6个月前

临床试验

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

Non Invasive Cancer Test (NICT): a Proof of Principle Study.

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

药物

BCG vaccine

Tamoxifen(Soltamox)

Raloxifene(Evista, Optruma, Raloxifene Teva)

机构

bioAffinity Technologies

CENTER WEST CANCER

Orsi Academy

资讯

LORD Trial Shows Active Surveillance May Be Safe Alternative to Surgery for Low-Risk DCIS

NIAGARA Trial: Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer

Johnson & Johnson's Erda-iDRS Shows 89% Complete Response Rate in First-in-Human Bladder Cancer Study